These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31228221)

  • 1. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
    Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
    Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
    Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
    BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study.
    Numata K; Tanaka K; Katsube T; Ochiai T; Fukuhara T; Kano T; Osaki Y; Izumi N; Imawari M
    Hepatol Res; 2020 Oct; 50(10):1141-1150. PubMed ID: 32609920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
    Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.
    Ding Z; Wu H; Zeng Y; Kuang M; Yang W; Meng Z; Chen Y; Hao C; Zou S; Sun H; Liu C; Lin K; Shi G; Wang X; Fu X; Chen R; Chen Y; Liang R; Kano T; Pan H; Yang S; Fan J; Zhou J
    Hepatol Int; 2023 Feb; 17(1):180-189. PubMed ID: 36258065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag.
    Brown RS; Imawari M; Izumi N; Osaki Y; Bentley R; Ochiai T; Kano T; Peck-Radosavljevic M
    JHEP Rep; 2021 Apr; 3(2):100228. PubMed ID: 33644726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
    Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
    Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
    Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
    Nishida Y; Kawaoka T; Imamura M; Namba M; Fujii Y; Uchikawa S; Ohya K; Daijo K; Teraoka Y; Morio K; Fujino H; Nakahara T; Yamauchi M; Hiramatsu A; Tsuge M; Aikata H; Takahashi S; Hayes CN; Fukuhara T; Tsuji K; Arataki K; Nagaoki Y; Aisaka Y; Kamada K; Kodama H; Chayama K
    Intern Med; 2021 Mar; 60(6):829-837. PubMed ID: 33087674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.